Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review

Int J Mol Sci. 2022 Feb 11;23(4):1987. doi: 10.3390/ijms23041987.

Abstract

The Coronavirus disease 2019 (COVID-19) pandemic poses a great threat to global public health. The original wild-type strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has genetically evolved, and several variants of concern (VOC) have emerged. On 26 November 2021, a new variant named Omicron (B.1.1.529) was designated as the fifth VOC, revealing that SARS-CoV-2 has the potential to go beyond the available therapies. The high number of mutations harboured on the spike protein make Omicron highly transmissible, less responsive to several of the currently used drugs, as well as potentially able to escape immune protection elicited by both vaccines and previous infection. We reviewed the latest publication and the most recent available literature on the Omicron variant, enlightening both reasons for concern and high hopes for new therapeutic strategies.

Keywords: B.1.1.529; COVID-19; Omicron; SARS-CoV-2; variants of concern.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / epidemiology*
  • COVID-19 / transmission
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • Humans
  • Immune Evasion
  • Mutation
  • Pandemics
  • Phylogeny
  • SARS-CoV-2 / classification
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / pathogenicity*
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / metabolism

Substances

  • Antibodies, Monoclonal
  • Antiviral Agents
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Supplementary concepts

  • SARS-CoV-2 variants